{"id":19423,"date":"2022-10-25T17:44:56","date_gmt":"2022-10-25T12:14:56","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=19423"},"modified":"2022-10-25T17:44:58","modified_gmt":"2022-10-25T12:14:58","slug":"pharma-news-for-sumitomo-abbvie-roche","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche","title":{"rendered":"Sumitomo to Purchase Myovant; AstraZeneca\u2019s Tremelimumab Plus Imfinzi Approved in the US; AbbVie Acquires DJS Antibodies; Roche and Hookipa Pharma Signs USD 25 Million Deal; FDA Accepts BMS\u2019s New Drug Application for CAMZYOS; Jazz and Zymeworks Sign Exclusive Licencing Agreement"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d64baa08f41\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d64baa08f41\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche\/#FDA_Accepts_Bristol_Myers_Squibbs_Supplemental_New_Drug_Application_for_CAMZYOS\" >FDA Accepts Bristol Myers Squibb\u2019s Supplemental New Drug Application for CAMZYOS<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche\/#Jazz_and_Zymeworks_Sign_Exclusive_Licencing_Agreement_for_Zanidatamab\" >Jazz and Zymeworks Sign Exclusive Licencing Agreement for Zanidatamab<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche\/#Sumitomo_Unit_Agrees_to_Purchase_Myovant_After_Raising_Bid\" >Sumitomo Unit Agrees to Purchase Myovant After Raising Bid<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche\/#AstraZenecas_Tremelimumab_Plus_Imfinzi_Combo_Approves_in_the_US\" >AstraZeneca\u2019s Tremelimumab Plus Imfinzi Combo Approves in the US<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche\/#AbbVie_Acquires_DJS_Antibodies_for_USD_255_Million_in_Cash\" >AbbVie Acquires DJS Antibodies for USD 255 Million in Cash<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche\/#Roche_and_Hookipa_Pharma_Signs_USD_25_Million_Deal_for_Arenaviral_Immunotherapy\" >Roche and Hookipa Pharma Signs USD 25 Million Deal for Arenaviral Immunotherapy&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-accepts-bristol-myers-squibb-s-supplemental-new-drug-application-for-camzyos\"><span class=\"ez-toc-section\" id=\"FDA_Accepts_Bristol_Myers_Squibbs_Supplemental_New_Drug_Application_for_CAMZYOS\"><\/span><strong>FDA Accepts Bristol Myers Squibb\u2019s Supplemental New Drug Application for CAMZYOS<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Bristol Myers Squibb<\/strong> declared that the <strong>U.S. FDA<\/strong> had accepted its supplemental new drug application for <strong>CAMZYOS <\/strong>for an expanded indication to reduce the need for <strong>septal reduction therapy<\/strong>. <strong>CAMYZOS <\/strong>is currently FDA-approved for treating adults with symptomatic New York Heart Association <strong>class II-III <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/hypertrophic-cardiomyopathy-market\"><strong>obstructive hypertrophic cardiomyopathy<\/strong><\/a> to improve functional capacity and symptoms.&nbsp;<\/p>\n\n\n\n<p>&#8220;Currently, it is suggested that many patients suffering with <strong>severe symptomatic obstructive hypertrophic cardiomyopathy<\/strong> undergo <strong>septal reduction therapy<\/strong>. This often requires either an <strong>open-heart surgical procedure<\/strong> or <strong>septal ablation procedure<\/strong>, both are specialized care options,&#8221; added Roland Chen, MD, senior vice president and head of cardiovascular development, Global Drug Development at Bristol Myers Squibb. &#8220;For patients, the approval of CAMZYOS earlier this year was a crucial turning point. If the FDA approves the application for this additional indication, it might boost CAMZYOS&#8217;s reputation while also reaffirming our commitment to providing patients with transforming <strong>cardiovascular treatments<\/strong>.&#8221;<\/p>\n\n\n\n<p>The <strong>sNDA submission<\/strong> was based on the results of <strong>Phase III VALOR-HCM<\/strong> study which is a randomized, double-blind, placebo-controlled study, which accessed <strong>CAMZYOS <\/strong>in patients with symptomatic, obstructive HCM who met the <strong>2011 ACC\/AHA<\/strong> guideline criteria for septal reduction therapy and who have been referred for an invasive procedure. VALOR-HCM met its primary and secondary endpoints with a high degree of statistical significance and no new safety signals observed.<\/p>\n\n\n\n<p><strong>VALOR-HCM<\/strong> is a <strong>randomized, double-blind, placebo-controlled, multicenter Phase III study<\/strong> of patients with <strong>symptomatic, obstructive HCM<\/strong>. They meet the guideline criteria for septal reduction therapy and have been referred for an invasive procedure. The study enrolled around 112 patients randomized on a 1:1 basis to receive mavacamten or a placebo. VALOR-HCM includes three treatment periods over a time duration of 128 weeks: a 16-week placebo-controlled period. During this 16-week active treatment period, all patients received mavacamten, and a 96-week long-term extension period where all patients received mavacamten.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Jazz_and_Zymeworks_Sign_Exclusive_Licencing_Agreement_for_Zanidatamab\"><\/span><strong>Jazz and Zymeworks Sign Exclusive Licencing Agreement for Zanidatamab<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Jazz Pharmaceuticals<\/strong> and <strong>Zymeworks <\/strong>declared that Jazz and Zymeworks&#8217; subsidiary, Zymeworks BC, has entered into an exclusive licensing agreement under which Jazz will acquire development and commercialization rights to Zymeworks&#8217; <strong>zanidatamab <\/strong>across all indications in the United States, Europe, Japan, and all other territories except for Asia-Pacific territories which are previously licensed by Zymeworks.<\/p>\n\n\n\n<p>In various <strong>HER2-expressing tumors<\/strong>, zanidatamab, a <strong>HER2-targeted bispecific antibody<\/strong> with unique mechanisms of action, has demonstrated potent anticancer effect when used alone or in combination with other therapies.&nbsp; Current pivotal trials are testing zanidatamab as the first-line therapy for <a href=\"https:\/\/www.delveinsight.com\/report-store\/gastroesophageal-adenocarcinoma-market\"><strong>HER2-positive gastroesophageal adenocarcinoma<\/strong><\/a> and the second-line therapy for HER2-expressing <a href=\"https:\/\/www.delveinsight.com\/report-store\/biliary-tract-cancers-btcs-market\"><strong>biliary tract cancer<\/strong><\/a>. The <strong>U.S. Food and Drug Administration<\/strong> has given zanidatamab the Breakthrough Therapy&nbsp; designation for biliary tract cancer, a disease for which no HER2-targeted treatments are currently approved and establishing it as a potential first-in-class treatment. Based on <strong>Phase II data<\/strong>, zanidatamab combined with chemotherapy may be a best-in-class treatment.<\/p>\n\n\n\n<p>Based on Zymeworks&#8217; Azymetric technology, zanidatamab has the ability to attach to two HER2 non-overlapping epitopes simultaneously. A number of unique modes of action, including dual HER2 signal blocking, improved binding and removal of the HER2 protein from the cell surface, and potent effector function are produced by this creative design, which promotes anticancer activity in patients.<\/p>\n\n\n\n<p>The FDA has given zanidatamab two Fast Track designations\u2014one as a single drug for refractory biliary tract cancer and the other in combination with standard-of-care chemotherapy\u2014for first-line GEA patients with HER2 gene-amplified biliary tract cancer who have previously received treatment. Due to these classifications, zanidatamab is qualified for <strong>Priority Review, Rolling Review<\/strong>, and <strong>Accelerated Approval<\/strong>, as well as FDA recommendations for a successful drug development program. Additionally, Zanidatamab has earned Orphan Drug designations from the European Medicines Agency for the treatment of gastric cancer and from the FDA for the treatment of <strong>biliary tract <\/strong>and <strong>gastric tumours<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sumitomo_Unit_Agrees_to_Purchase_Myovant_After_Raising_Bid\"><\/span><strong>Sumitomo Unit Agrees to Purchase Myovant After Raising Bid<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>After its initial offer was rejected, <strong>Sumitomo Pharma&#8217;s<\/strong> sweetened offer persuaded endocrinology specialist Myovant to agree to a takeover. <strong>Sumitomo <\/strong>and its subsidiary <strong>Sumitovant Biopharma<\/strong> initially offered <strong>USD 22.75<\/strong> per share for <strong>Myovant<\/strong>, which develops hormonal therapies for conditions such as uterine fibroids, endometriosis, and prostate cancer, but this was deemed insufficient and was rejected earlier this month.<\/p>\n\n\n\n<p>Now, a <strong>USD 27<\/strong> per share offer has persuaded <strong>Myovant&#8217;s <\/strong>board to accept the offer, which comes nearly three years after Sumitomo purchased a <strong>46%<\/strong> stake in Myovant as part of a strategic-level, <strong>USD 3 billion<\/strong> deal that formed Sumitovant from five Roivant group companies.<\/p>\n\n\n\n<p>Sumitomo already owned approximately <strong>52%<\/strong> of the company prior to the new offer, which values Myovant at approximately <strong>USD 2.9 billion,<\/strong> and is spending <strong>USD 1.7 billion<\/strong> to acquire <strong>100%<\/strong> ownership of its shares. Myovant stated in a market update that the purchase price represents a <strong>50%<\/strong> premium over its closing share price on September 30, the last day of trading prior to <strong>Sumitovant&#8217;s <\/strong>first offer.&nbsp;<\/p>\n\n\n\n<p>Sumitomo will gain control of <strong>Myovant&#8217;s Pfizer<\/strong>-partnered oral GnRH antagonist <strong>Myfembree (relugolix),<\/strong> which was approved last year to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/uterine-fibroids-market\">uterine fibroids<\/a>, as well as another formulation of the same drug called <strong>Orgovyx<\/strong>, which is used to treat prostate cancer, under the terms of the agreement, which is expected to close in the first quarter of 2023. In Myovant&#8217;s fiscal first quarter, which ended on June 30, 2022, sales of the two products were <strong>USD 4 million and USD 36 million<\/strong>, respectively.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AstraZenecas_Tremelimumab_Plus_Imfinzi_Combo_Approves_in_the_US\"><\/span><strong>AstraZeneca\u2019s Tremelimumab Plus Imfinzi Combo Approves in the US<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Tremelimumab<\/strong>, a CTLA4 inhibitor developed by <strong>AstraZeneca<\/strong>, has received regulatory approval as part of a combination therapy for advanced liver cancer. Tremelimumab was approved by the FDA in the United States for use in combination with <strong>AstraZeneca&#8217;s PD-L1 inhibitor<\/strong> <strong>Imfinzi (durvalumab) <\/strong>to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatocellular-carcinoma-market\">adults with unresectable hepatocellular carcinoma<\/a> (HCC), the most common type of liver tumor.<\/p>\n\n\n\n<p>The CTLA4 inhibitor, now known as <strong>Imjudo<\/strong>, is only the second drug in the class to be approved, following <strong>Bristol-Myers Squibb&#8217;s<\/strong> well-known <strong>Yervoy (ipilimumab)<\/strong>, which is used alongside <strong>BMS&#8217; PD-1 inhibitor Opdivo (nivolumab)<\/strong> in a variety of solid tumors, including HCC and lung, colorectal, skin, and kidney cancers.<\/p>\n\n\n\n<p>In previously untreated HCC patients, the FDA approved a single <strong>300 mg dose<\/strong> of <strong>Imjudo <\/strong>given alongside <strong>1,500 mg Imfinzi<\/strong>, followed by Imfinzi every four weeks &#8211; known as the <strong>STRIDE <\/strong>(single tremelimumab regular interval durvalumab) regimen.<\/p>\n\n\n\n<p>AstraZeneca sees the first-line HCC indication as a significant opportunity for its immuno-oncology franchise, so it used a priority review voucher &#8211; typically valued at around <strong>USD 100 million<\/strong> &#8211; to reduce the FDA review time for the application to six months.<\/p>\n\n\n\n<p>In the <strong>HIMALAYA trial<\/strong>, patients treated with the <strong>STRIDE <\/strong>regimen had a <strong>22%<\/strong> lower risk of death compared to <strong>Nexavar<\/strong>, and nearly one-third of patients (<strong>31%<\/strong>) were still alive after three years, compared to <strong>20%<\/strong> in the control group. The study defied the trend of tremelimumab, adding little or nothing to Imfinzi in various cancer types while increasing the side-effect burden of therapy. <strong>Yervoy <\/strong>is also known to be difficult to tolerate.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"AbbVie_Acquires_DJS_Antibodies_for_USD_255_Million_in_Cash\"><\/span><strong>AbbVie Acquires DJS Antibodies for USD 255 Million in Cash<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On October 20, 2022, <strong>AbbVie <\/strong>announced the acquisition of <strong>DJS Antibodies Ltd.<\/strong>, a privately-held UK-based biotechnology company dedicated to discovering and developing the next generation of antibody therapeutics products that target difficult-to-drug disease-causing proteins, such as G protein-coupled receptors (GPCRs). As per the agreement, AbbVie will pay DJS shareholders approximately <strong>$255 million<\/strong> in cash at closing for the acquisition of DJS. Furthermore, AbbVie is planning to retain all current DJS employees and its facility in Oxford. <strong>Oxford Science Enterprises <\/strong>and <strong>Johnson &amp; Johnson Innovation Ltd.<\/strong>, along with <strong>LifeArc, Sedgwick Yard, and Amgen Ventures<\/strong>, are some of the founding investors backed by DJS.<\/p>\n\n\n\n<p>DJS leverages a proprietary <strong>HEPTAD platform<\/strong> for the antibody discovery to GPCRs and other intractable targets.<strong> DJS-002<\/strong> is one of the lead candidates of the DJS, the therapy is currently in the investigational preclinical studies. DJS-002 is a potential <a href=\"https:\/\/www.delveinsight.com\/report-store\/type-1-lysophosphatidic-acid-receptor-lpa1-inhibitor-pipeline-insight\"><strong>first-in-class lysophosphatidic acid (LPA) receptor 1 (LPAR1) antagonist antibody<\/strong><\/a> for the <a href=\"https:\/\/www.delveinsight.com\/report-store\/idiopathic-pulmonary-fibrosis-market\"><strong>treatment of Idiopathic Pulmonary Fibrosis (IPF)<\/strong><\/a> and other fibrotic diseases. Moreover, upon achieving certain development milestones related to the DJS-002 program, the DJS shareholders remain eligible for potential additional payments.&nbsp;<\/p>\n\n\n\n<p>AbbVie has a remarkable presence across several key therapeutic areas, such as immunology, oncology, neuroscience, eye care, virology, and gastroenterology. The latest acquisition of DJS Antibodies is expected to strengthen AbbVie\u2019s immunology pipeline further. It will provide new capabilities to enhance AbbVie\u2019s current antibody research activities and will expand the research efforts in the immunology segment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Roche_and_Hookipa_Pharma_Signs_USD_25_Million_Deal_for_Arenaviral_Immunotherapy\"><\/span><strong>Roche and Hookipa Pharma Signs USD 25 Million Deal for Arenaviral Immunotherapy&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On October 20, 2022, <strong>HOOKIPA Pharma Inc<\/strong>. announced a strategic collaboration and license agreement with <strong>Roche <\/strong>to develop <strong>HB-700<\/strong> for KRAS-mutated cancers and a second undisclosed novel arenaviral immunotherapy. <strong>HOOKIPA Pharma<\/strong> is a clinical-stage biopharmaceutical company developing a new class of immunotherapies based on its proprietary arenavirus platform. It is the first oncology licensing collaboration of HOOKIPA.&nbsp;<\/p>\n\n\n\n<p>As per the update by HOOKIPA, through the collaboration, HOOKIPA will conduct research and early clinical development through Phase 1b for HB-700. HB-700 is a novel investigational arenaviral immunotherapy designed to treat <a href=\"https:\/\/www.delveinsight.com\/report-store\/kras-mutant-cancer-pipeline-insight\"><strong>KRAS-mutated lung cancer<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/colorectal-cancer-crc-market\"><strong>colorectal cancer,<\/strong><\/a> <a href=\"https:\/\/www.delveinsight.com\/report-store\/pancreatic-cancer-market\"><strong>pancreatic cancer<\/strong><\/a>, and other cancers. HB-700 is a replicating 2-vector therapy that targets the most common KRAS mutations: (G12D, G12V, G12R, G12C, and G13D) and thereby benefit more patients than single mutation inhibitors. Upon completing the Phase 1b trial, Roche has the right to assume development responsibility and commercialize licensed products across multiple indications after approval. The agreement also includes an option for Roche to license second <a href=\"https:\/\/www.delveinsight.com\/report-store\/lag-3-next-generation-immunotherapy-competitive-landscape\"><strong>arenaviral cancer immunotherapy<\/strong><\/a>.<\/p>\n\n\n\n<p>Furthermore, HOOKIPA will get a <strong>$25 million u<\/strong>pfront payment per the contract terms. HOOKIPA will earn an extra <strong>$15 million payment<\/strong> upon the option exercise if Roche chooses to extend the first agreement by adding a new product candidate. Including this option payment, HOOKIPA is qualified for research, development, and commercialization milestone-based payments totaling approximately <strong>$930 million<\/strong>. Upon commercialization, HOOKIPA is eligible to receive tier-based royalties on the global net sales of HB-700 and the additional product candidate that range from a high single-digit to a mid-teens percentage.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA Accepts Bristol Myers Squibb\u2019s Supplemental New Drug Application for CAMZYOS Bristol Myers Squibb declared that the U.S. FDA had accepted its supplemental new drug application for CAMZYOS for an expanded indication to reduce the need for septal reduction therapy. CAMYZOS is currently FDA-approved for treating adults with symptomatic New York Heart Association class II-III [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":19426,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19861,5996,651,19862,349,365,420,18316,639],"industry":[17225],"therapeutic_areas":[17242,17228,17243],"class_list":["post-19423","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-fda-approvals","tag-hepatocellular-carcinoma","tag-idiopathic-pulmonary-fibrosis","tag-kras-mutated-cancers","tag-latest-pharma-news","tag-lung-cancer","tag-news","tag-obstructive-hypertrophic-cardiomyopathy","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-oncology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News Updates | Sumitomo, AstraZeneca, AbbVie, Roche, BMS<\/title>\n<meta name=\"description\" content=\"AbbVie acquires DJS; Roche-Hookipa\u2019s deal; BMS\u2019s CAMZYOS; Jazz-Zymeworks sign agreement; AstraZeneca\u2019s tremelimumab; Myovant&#039;s acquisition\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News Updates | Sumitomo, AstraZeneca, AbbVie, Roche, BMS\" \/>\n<meta property=\"og:description\" content=\"AbbVie acquires DJS; Roche-Hookipa\u2019s deal; BMS\u2019s CAMZYOS; Jazz-Zymeworks sign agreement; AstraZeneca\u2019s tremelimumab; Myovant&#039;s acquisition\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-25T12:14:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-25T12:14:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/25173639\/Pharma-News-Updates-for-Sumitomo-AstraZeneca-and-AbbVie.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News Updates | Sumitomo, AstraZeneca, AbbVie, Roche, BMS","description":"AbbVie acquires DJS; Roche-Hookipa\u2019s deal; BMS\u2019s CAMZYOS; Jazz-Zymeworks sign agreement; AstraZeneca\u2019s tremelimumab; Myovant's acquisition","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche","og_locale":"en_US","og_type":"article","og_title":"Pharma News Updates | Sumitomo, AstraZeneca, AbbVie, Roche, BMS","og_description":"AbbVie acquires DJS; Roche-Hookipa\u2019s deal; BMS\u2019s CAMZYOS; Jazz-Zymeworks sign agreement; AstraZeneca\u2019s tremelimumab; Myovant's acquisition","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2022-10-25T12:14:56+00:00","article_modified_time":"2022-10-25T12:14:58+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/25173639\/Pharma-News-Updates-for-Sumitomo-AstraZeneca-and-AbbVie.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche","name":"Pharma News Updates | Sumitomo, AstraZeneca, AbbVie, Roche, BMS","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/25173639\/Pharma-News-Updates-for-Sumitomo-AstraZeneca-and-AbbVie.png","datePublished":"2022-10-25T12:14:56+00:00","dateModified":"2022-10-25T12:14:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"AbbVie acquires DJS; Roche-Hookipa\u2019s deal; BMS\u2019s CAMZYOS; Jazz-Zymeworks sign agreement; AstraZeneca\u2019s tremelimumab; Myovant's acquisition","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-sumitomo-abbvie-roche#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/25173639\/Pharma-News-Updates-for-Sumitomo-AstraZeneca-and-AbbVie.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/25173639\/Pharma-News-Updates-for-Sumitomo-AstraZeneca-and-AbbVie.png","width":772,"height":482,"caption":"Pharma News Updates for Sumitomo, AstraZeneca, and AbbVie"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2022\/10\/25173639\/Pharma-News-Updates-for-Sumitomo-AstraZeneca-and-AbbVie-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA Approvals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hepatocellular Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">KRAS-mutated cancers<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lung Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Obstructive Hypertrophic Cardiomyopathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">FDA Approvals<\/span>","<span class=\"advgb-post-tax-term\">Hepatocellular Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">Idiopathic Pulmonary Fibrosis<\/span>","<span class=\"advgb-post-tax-term\">KRAS-mutated cancers<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Lung Cancer<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Obstructive Hypertrophic Cardiomyopathy<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Oct 25, 2022","modified":"Updated on Oct 25, 2022"},"absolute_dates_time":{"created":"Posted on Oct 25, 2022 5:44 pm","modified":"Updated on Oct 25, 2022 5:44 pm"},"featured_img_caption":"Pharma News Updates for Sumitomo, AstraZeneca, and AbbVie","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=19423"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/19423\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/19426"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=19423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=19423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=19423"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=19423"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=19423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}